In response to questions from Senator Kirsten Gillibrand’s (D-NY) office, the Bureau of International Narcotics and Law Enforcement at the State Department has gone on record that the U.S. could issue multiple licenses for the cultivation of cannabis for medical and scientific purposes without violating the U.N. Single Convention on Narcotic Drugs. This interpretation is at odds with Drug Enforcement Administration’s (DEA) interpretation that the treaty only allows a single license, which is granted to the National Institute on Drug Abuse (NIDA) creating the “NIDA-monopoly on cannabis,”which has stalled medical cannabis research for years.
According, to NIH:
Under the 1961 international Single Convention on Narcotic Drugs (amended in 1972), cannabis is designated a Schedule I substance, and participating countries are required to restrict production, manufacture, possession and distribution of marijuana except for medical and scientific purposes. The Drug Enforcement Administration (DEA) regulates the cultivation of marijuana for research purposes through licensing requirements and establishing annual aggregate production quotas under the authority of the 1970 Controlled Substances Act (CSA), which implements the Single Convention. To date, the DEA has only issued a single license for the cultivation of marijuana for research, to the University of Mississippi, which is funded through a NIDA contract. Questions on the authority to issue additional licenses would have to be addressed to the DEA.